目的:了解武汉地区34家医院抗血小板药和抗凝血药临床应用情况,为临床合理用药提供参考。方法:采用回顾性分析方法,对2011~2013年武汉地区34家医院抗血小板药和抗凝血药的销售金额、各药品品种的销售金额、用药频度(DDDs)、药品限定日费用(DDC)和排序比(B/A)进行统计分析。结果:抗血小板药和抗凝血药的销售金额逐年呈上升趋势,氯吡格雷、红花、低分子量肝素销售金额每年均排在前3位;氯吡格雷、华法林、肝素、低分子量肝素、红花DDDs位居前5位,华法林、肝素的DDC小于10元/d;肝素、西洛他唑、舒洛地特、蚓激酶、华法林、吲哚布芬B/A值超过1。结论:武汉地区34家医院抗血小板药和抗凝血药临床应用中,氯吡格雷、华法林、肝素和低分子肝素占主导地位,吲哚布芬、达比加群酯前景可观。 Objective: To understand the clinical application of antiplatelet drugs and anticoagulants in 34 hospitals in Wuhan, and to provide reference for clinical rational drug use. Methods: A retrospective analysis was conducted on the sales amount of antiplatelet drugs and anticoagulants in 34 hospitals in Wuhan from 2011 to 2013, the sales amount, DDDs, DDC ) And sorting ratio (B / A) for statistical analysis. Results: The sales amount of anti-platelet drugs and anticoagulants increased year by year. Sales amount of clopidogrel, safflower and low molecular weight heparin ranked the top three each year; clopidogrel, warfarin, heparin, low molecular weight Heparin, safflower DDDs top 5, warfarin, heparin DDC less than 10 yuan / d; heparin, cilostazol, sulodexide, lumbrokinase, warfarin, indobufen B / A Value exceeds 1. Conclusion: Clopidogrel, warfarin, heparin and LMWH dominate the clinical application of antiplatelet agents and anticoagulants in 34 hospitals in Wuhan. Indobufen and dabigatran are promising.